-
Global Quality, Chinese Evidence｜Prof. Qingyuan Zhang: Lerociclib Brings a New CDK4/6i Option for Breast Cancer Patients
Message from Prof. Qingyuan Zhang: “Patients with HR+/HER2– advanced breast cancer have an urgent need for more effective and tolerable therapies. As a structurally optimized new-generation CDK4/6 inhibitor, Lerociclib has…
-
Breaking News｜Lerociclib (Rujianing®) Begins Clinical Use, Redefining HR+ Breast Cancer Care in China
This approval signifies that China’s HR+/HER2– breast cancer treatment has entered a new era. Now, just over three months later, the first clinical prescriptions for Lerociclib in combination with aromatase…
-
2025 COMB · Oncology Frontier Sofa Dialogue丨Professors Tao Wang & Kun Wang: Charting the Future of Chinese Original Research in Breast Cancer
01 Oncology Frontier: At this meeting, you presented multiple original Chinese studies in HER2-positive breast cancer, including Professor Kun Wang’s neoCARHP trial. Among them, which captured your particular attention? Could…
-
Professor Sun Ruijuan: Optimizing Key Aspects of Hematopoietic Stem Cell Transplantation for Infant Leukemia | 13th Ludaopei Hematology Conference
On August 22–23, 2025, the 13th Ludaopei Hematology Conference was grandly held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…
-
Professor Cao Xingyu: Clinical Management and Transplant Strategies in Mycosis Fungoides and Sézary Syndrome | 13th Ludaopei Hematology Conference
On August 22–23, 2025, the 13th Ludaopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease Foundation,…
-
Professor Jin Li & Professor Joon Oh Park: Carrying the Torch Forward with Unity and Collaboration — FACO as a Platform for Advancing Comprehensive Academic Cooperation and the Joint Progress of Asian Clinical Oncology
Themed “Asian Clinical Oncology—Collaboration and Innovation,” this year’s FACO meeting aimed to further strengthen academic exchange and cross-border cooperation, while helping China’s rapidly evolving innovative oncology therapeutics “go global” to…
-
ISEH 2025 | Harvesting the Fruits of Collaboration: China–Japan Symposium on Stem Cells and Cell Therapy Opens a New Chapter
Launching a New Chapter: Forty Years of Sino–Japanese Exchange in Hematology The symposium began with opening remarks from Prof. Tao Cheng, Director of the Institute of Hematology, CAMS. He recalled…
Connecting Medical Expertise through Media